Viewing Study NCT02260193

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:12 AM
Ignite Modification Date: 2026-02-24 @ 5:50 AM
Study NCT ID: NCT02260193
Status: COMPLETED
Last Update Posted: 2022-07-01
First Post: 2014-09-25
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Sponsor: Akebia Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anemia View
None End Stage Renal Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None anemia View
None end stage renal disease View
None chronic kidney disease View
None CKD View
None dialysis View
None chronic renal insufficiency View
None renal impairment View
None erythropoietin View
None kidney View
None oral anemia treatment View
None hemoglobin View
None hypoxia-inducible factor View
None HIF View
None hypoxia-inducible factor propyl-hydroxylase inhibitor View
None HIF-PHI View
None pharmacokinetics View